| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.002 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.086 | 0.002 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.14 | 0.005 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.093 | 0.005 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.098 | 0.006 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |